Is stent thrombosis the new Achilles heel of interventional cardiology? State of the Art clinical trials, causes and approaches for prevention;Ist die Stentthrombose die neue Achillesferse der interventionellen Kardiologie? Aktuelle Studienlage, Ursachen und Ansätze zur Prävention

Hamostaseologie

Volumn 27, Issue 5, 2007, Pages 344-350

  Grumann, Thorsten ^a   Diehl, P ^a   Bode, C ^a   Moser, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

DES; Platelet aggregation; Stent thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; ELECTRON MICROSCOPY; FIBRINOLYTIC THERAPY; HUMAN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENT;

CLINICAL TRIALS AS TOPIC; CORONARY THROMBOSIS; HUMANS; MICROSCOPY, ELECTRON; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STENTS; THROMBOLYTIC THERAPY;

EID: 38749117581     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617003     Document Type: Article

References (67)

1. Beohar N, Davidson CJ, Kip KEet al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297: 1992-2000.
2. Bertrand ME, Rupprecht HJ, Urban P et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
3. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
4. Biondi-Zoccai GG, Sangiorgi GM, Chieffo A et al. Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol 2005; 95: 1466-1468.
5. Butzal M, Loges S, Schweizer M et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004; 300: 65-71.
6. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drugeluting stents: a cause for concern. Circulation 2007; 115: 1440-1455.
7. Camici GG, Steffel J, Akhmedov A et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drugeluting stents. Circulation 2006; 114: 1512-1521.
8. Chen MS, John JM, Chew DP et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264.
9. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif. 2006; 39: 117-125.
10. Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-1971.
11. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
12. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimuseluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
13. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
14. Duckers H. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroInterv 2007; 3: 67-75.
15. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
16. Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
17. Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
18. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
19. Fujii K, Carlier SG, Mintz GS et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimuseluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995-998.
20. Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am Heart J 2006; 151: 689 e1- e10.
21. Grossmann R, Sokolova O, Schnurr A et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
22. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
23. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
24. Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-395.
25. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
26. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46: 1446-1455.
27. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
28. Jeremias A, Sylvia B, Bridges J et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
29. Joner M, Finn AV, Farb A et al. Pathology of drugeluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
30. Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation baremetal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921-929.
31. Karrillon GJ, Morice MC, Benveniste E et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 1996; 94: 1519-1527.
32. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
33. Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
34. Lagerqvist B, James SK, Stenestrand U et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
35. Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
36. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671.
37. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
38. Matter CM, Rozenberg I, Jaschko A et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006; 48: 286-292.
39. Mauri L, Hsieh WH, Massaro JM et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
40. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
41. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
42. Menichelli M, Parma A, Pucci E et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). JAm Coll Cardiol 2007; 49: 1924-1930.
43. Mueller T, Dieplinger B, Poelz W et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer-comparison with two flow cytometric methods. Thromb Res 2007 May 4.
44. Ong AT, Hoye A, Aoki J et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-953.
45. Parry TJ, Brosius R, Thyagarajan R et al. Drugeluting stents: sirolimus and paclitaxel differen-tially affect cultured cells and injured arteries. Eur J Pharmacol 2005; 524: 19-29.
46. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
47. Sane DC, McKee SA, Malinin AI et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 893-895.
48. Schuhlen H, Kastrati A, Mehilli J et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004; 147: 317-322.
49. Serebruany VL, Steinhubl SR, Berger PB et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-1222.
50. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006; 354: 483-495.
51. Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
52. Siller-Matula J, Schror K, Wojta J et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
53. Spaulding C, Daemen J, Boersma E et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
54. Spaulding C, Henry P, Teiger E et al. Sirolimuseluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
55. Stahli BE, Camici GG, Steffel J et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 2006; 99:149-155.
56. Steffel J, Hermann M, Greutert H et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005; 111: 1685-1689.
57. Steffel J, Latini RA, Akhmedov A et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005; 112: 2002-2011.
58. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
59. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
60. Ten Berg JM, Plokker HT, Verheugt FW. Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention. Curr Control Trials Cardiovasc Med 2001; 2: 129-140.
61. Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-1441.
62. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
63. Von Beckerath N, Taubert D, Pogatsa-Murray G et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
64. Wenaweser P, Rey C, Eberli FR et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26: 1180-1187.
65. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006; 114: 2154-2162.
66. Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following offlabel use of drug-eluting stents. JAMA 2007; 297: 2001-2009.
67. Zhu S, Viswambharan H, Gajanayake T et al. Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovasc Disord 2005; 5: 22.